Drug Profile
Research programme: neurodegenerative therapeutics - Prothena/The University of Cambridge
Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Prothena; University of Cambridge
- Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Protein aggregation modulators; Protein conformation modulators; Protein folding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease